Key result
SGLT2i and GLP-1RA reduce MACE and improve cardiovascular health with or without T2D.
Why the study?
Recent investigations have unveiled multifaceted cardiovascular benefits of SGLT2i and GLP1-RA extending beyond glucose lowering, warranting a review of their diverse mechanisms of action.
SGLT2 inhibitors and GLP1 receptor agonists offer significant cardiovascular protection in patients with and without T2DM, likely mediated by anti-inflammatory and anti-oxidative effects.
May support expanded CV protection with SGLT2 inhibitors and GLP-1 agonists beyond diabetes; leaves open antioxidant mediation.
Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.
No takes yet. Share an insight, caveat, or question.
Myasoedova et al. (2023) conducted a review in Type 2 diabetes mellitus and cardiovascular diseases. SGLT2 inhibitors and GLP1 receptor agonists was evaluated. SGLT2 inhibitors and GLP1 receptor agonists demonstrate multifaceted benefits in reducing major cardiovascular events and improving cardiovascular health in patients with and without type 2 diabetes.